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Inhibition of microvesiculation 
sensitizes prostate cancer cells 
to chemotherapy and reduces 
docetaxel dose required to limit 
tumor growth in vivo
Samireh Jorfi1, Ephraim A. Ansa-Addo1,†, Sharad Kholia1, Dan Stratton1, Shaunelle Valley1, 
Sigrun Lange2 & Jameel Inal1
Microvesicles shed from cells carry constituents of the cell cytoplasm, including, of importance in 
multidrug resistance to cancer chemotherapy, drugs that the tumor cell attempts to efflux. To see 
whether such drugs could be used at lower concentrations with the same efficacy, it was first shown 
that microvesiculation of prostate cancer (PCa) cells, PC3, could be inhibited pharmacologically 
with calpeptin (calpain inhibitor) and by siRNA (CAPNS1). In cells treated with docetaxel (DTX), 
this inhibition resulted in a third-fold increase in intracellular concentrations of DTX. As a result, 
20-fold lower concentrations of DTX (5 nM) could be used, in the presence of calpeptin (20 μM) 
inducing the same degree of apoptosis after 48 h in PC3 cells, as 100 nM of DTX alone. Inhibition 
of microvesiculation similarly improved combination chemotherapy (DTX and methotrexate). In a 
mouse xenograft model of PCa, DTX (0.1 mg/kg) together with calpeptin (10 mg/kg), administered 
i.p., significantly reduced tumor volumes compared to DTX alone (0.1 mg/kg) and brought about 
the same reductions in tumor growth as 10 mg/kg of DTX alone. As well as further reducing 
vascularization, it also increased apoptosis and reduced proliferation of PC3 cells in tumor xenografts.
Multidrug resistance (MDR) in solid tumors of which there are two types, intrinsic, present before treat-
ment, and acquired which develops during treatment1 remains an unresolved problem in cancer chemo-
therapy. To compound the problem, multiple pathways are affected in MDR, acting synergistically to 
develop resistance1.
The ABC transporter superfamily members are involved in drug efflux. P glycoprotein, P-gp was the 
first protein found to confer drug resistance on cultured cells2 and the Multidrug-Resistance-associated 
Protein (MRP1) is involved in the resistance of lung cancer cells3. P-gp inhibitors such as cyclosporine and 
valspodar, however, are promiscuous in terms of transporter specificity4. Although P-gp is not expressed 
in PCa cell lines, it was instrumental in proving a non-genetic mechanism involved in multidrug resist-
ance by co-culturing P-gp positive chemo-resistant leukemic cells with P-gp negative, chemo-sensitive 
cells, resulting in direct cell-cell transfer and expression of P-gp5. Others went further to elucidate the 
mechanism, showing microvesicle- (MV-) mediated transfer6. Although docetaxel (DTX) is used in the 
treatment of metastatic castrate-resistant PCa, many patients do not respond to DTX therapy and all 
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will inevitably develop resistance7. Therefore the understanding of the mechanisms by which resistance 
develops is necessary to develop novel therapies.
In practise, drug resistance occurs due to changes in the rate of drug uptake and efflux, altered drug 
metabolism, decreased drug-target complex formation or enhanced DNA repair mechanisms8. More spe-
cific examples include decreased expression of reduced folate carrier (RFC) associated with methotrexate 
(MTX) resistance2, and resistance to DTX resulting from mutation at the drug binding site of tubulin 
and the expression of different tubulin isoforms9. In this study, however, we focused our attention on the 
removal of chemotherapeutic drugs from cancer cells through the release of MVs.
Microvesicles are small plasma membrane-derived vesicles present in blood, urine and other body 
fluids that carry cytosolic and plasma membrane constituents from the parent cells, including bioactive 
molecules, proteins, mRNAs and miRNAs; their roles in diagnosis, prognosis and in surveillance of 
diseases have become increasingly apparent in recent times10. Cancer cells release MVs to protect them-
selves against intracellular stress and inhibition of this release leads to accumulation of caspase-3 and cell 
apoptosis11. MVs released from cancer cells containing chemotherapeutic agents, aid drug resistance and 
interact with the immune system to suppress immune response to tumors12. Cancer cells may also hide 
from the immune system by fusing with healthy MVs, expressing their membrane-specific proteins13 and 
may go on to aid cancer progression through the metalloproteases they carry, facilitating extracellular 
matrix degradation14,15. In terms of drug therapy and MVs we became interested in increased efflux of 
anticancer drugs16,17 mediated by MVs as a mechanism for multidrug resistance.
DTX binds β -tubulin monomers. By thus stabilizing microtubules and preventing their depolymeriza-
tion, microtubular dynamics is effectively arrested which impacts on a host of essential cellular functions. 
Inhibition of mitotic cell division blocks cells in the G2/M phase, thus inhibiting cell proliferation. DTX 
also inhibits early endosomal uptake and secretion. MTX, which we also used in this study, however, is 
an antimetabolite and antifolate drug, that inhibits DNA, RNA and protein synthesis.
Calpains comprise a family of calcium-dependent intracellular cysteine proteases involved in processes 
important for tumor progression including apoptosis, proliferation, cell migration and invasiveness. Most 
calpain activity is due to μ - and m- calpains (or Calpain-1 (CAPN1) and Calpain-2 (CAPN2), respec-
tively); these calpains in turn require μ M and mM concentrations of calcium to function. They are het-
erodimers comprising a large 80 kDa catalytic subunit and a shared 28 kDa regulatory subunit, CAPNS1 
(calpain small-1) (sometimes called Calpain-4). In tumor cells calpain is usually hyperactivated and due 
to its ability to cleave cytoskeleton is involved in tumor migration and metastasis. Calpeptin is therefore 
a cell-permeable protease inhibitor which selectively inhibits calpains and reduces MV release18–20.
We believed drug-detoxification by cancer cells based on MV release could explain the cells’ insensi-
tivity to drug-induced apoptosis and so the aim of this study was to improve cancer chemotherapy and 
circumvent drug resistance through regulation of MV release. By knocking down CAPNS1 expression 
with siRNA or pharmacologically inhibiting it with calpeptin, we wanted to see if this could sensitize 
cancer cells to chemotherapy allowing a reduction in the effective drug dosage.
Methods
Ethical statement. All experimental protocols in this study were carried out in accordance with 
approved guidelines (Faculty safety code of practice) and all experimental protocols were approved by 
the Faculty of Life Sciences (FLS), including the FLS London Metropolitan University Research Ethics 
Review panel and Genetic Modifications Safety Committee. The intraperitoneal (i.p.) xenograft model 
of human PCa was carried out at Washington Biotechnology (Baltimore, MD), (U.S. Department of 
Agriculture (USDA) Registration No. 51-R-031 and Accreditation No. A4192-01) where animal care was 
according to the Public Health Services guideline, and in accordance with the Office for Laboratory and 
Animal Welfare division of the National Institutes of Health.
Knockdown of CAPNS1 by small  interfering RNA (siRNA) transfection.  GeneSolution siRNA 
sequences targeted to four different sites in calpain small subunit 1, CAPNS1 mRNA (GenBank Accession 
No. X04106) and negative control siRNA (Qiagen, Crawley, UK) were reconstituted in sterile RNase-free 
water at a final concentration of 10 μ M. PC3 cells (5 × 104/well in triplicate) were transfected with 5 or 
50 nM siRNA (final concentration), using HiPerfect transfection reagent (HPP, Qiagen) for 48 h prior to 
performing experiments. The sequences for the human CAPNS1 siRNAs are indicated in Supplementary 
Fig. 1. Consistent reduction of CAPNS1 expression was observed with siRNA#6 which was used to assess 
the effects of decreasing CAPNS1 levels on the sensitivity of PC3 cells to drug resistance.
Immunoblotting analysis of siRNA transfected cells. Control or CAPNS1 knocked down PC3 
cells, were treated with lysis buffer (100 mM HEPES/KOH, 2 mM CaCl2, 0.5% Triton X-100) containing 
a protease inhibitor cocktail (Sigma-Aldrich). Protein lysate concentrations were measured using the 
BCA assay kit (Pierce Biosciences)21 and 20 μ g resolved by SDS-PAGE on a 12% polyacrylamide gel21. 
Immunoblotting was carried out as described before21, this time being incubated with anti-β -actin or 
anti-CAPNS1 (CAPNS1) (both Sigma-Aldrich), diluted 1/500 in PBST (PBS with 0.1% (v/v) Tween 20). 
After incubating with secondary antibodies, protein bands were visualised using the LumiGOLD ECL 
Western Blotting Detection kit (SignaGen Laboratories), the chemiluminescence signal being detected 
on the ChemiDoc-It Imaging System (UVP, Cambridge).
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Cell culture and proliferation assay. Adherent PC3 cells were maintained at 37 °C with 5% CO2, in 
RPMI growth medium, and split, depending on confluency, every 3 to 5 days. The number of cells and 
viability were determined before the start of every experiment using the flow cytometer (ViaCount assay, 
Guava Technologies), exponentially growing cells with viability of 95% or higher being routinely used. 
To measure proliferation and any inhibitory effect of CP in combination with DTX treatment, PC3 cells 
were seeded at 5 × 104 cells per well in 6-well plates and 24 h later given 5 nM DTX with or without CP 
(20 μ M), control cells being given DMSO (0.01%). Cells at 1, 2 and 3 day time points were detached with 
trypsin and after trypan blue staining (0.4%) counted on a haemocytometer.
Isolation and analysis of microvesicles from conditioned medium. Isolation and analysis of 
MVs, which included enumeration by nanosight tracking analysis (NTA) detection of phosphatidylser-
ine (PS) by flow cytometry (Guava EasyCyte, Guava Technologies) and the use of electron microscopy 
to confirm size and purity was essentially carried out as described before21–27 with some modifications.
To purify MVs, cell culture supernatants were centrifuged at 200 g for 5 min to remove cells, 4,000 g 
for 1 h to remove cell debris and then at 15,000 g for 2 h to pellet MVs. After washing in exosome and 
MV-(EMV-) free, sterile PBS, the pellet was resuspended in EMV-free PBS and quantified by nanosight 
tracking analysis (NTA). The nanosight used to enumerate MVs was the NS500 (Nanosight, Amesbury, 
UK), equipped with a sCMOS camera and a 405 nm diode laser. Data acquisition and processing were 
performed using NTA software 3.0. Background extraction and automatic settings were applied for the 
minimum expected particle size, minimum track length and blur, the ambient temperature being set 
at 23 °C. Silica beads (100 nm diameter; Microspheres-Nanospheres, Cold Spring, NY) were used to 
calibrate the NS500. Samples were diluted 10–50 fold in EMV-free PBS to maintain the number of par-
ticles in the field of view between approximately 20–40. For each sample, 4 × 30 s videos were recorded, 
replicate histograms being averaged. Analysis was only carried out on measurements with at least 1000 
completed tracks.
DTX-  and MTX-mediated  apoptosis  of  PC3  cells.  PC3 cells seeded at 5 × 104/well in triplicate 
were washed after 24 h and treated with calpeptin (CP) (20 μ M for 45 min), re-washed and resuspended 
in varying concentrations of MTX and DTX for 48 h. DTX/MTX-induced apoptosis levels in the pres-
ence or absence of CP were assayed using Guava ViaCount by flow cytometry.
Drug extraction from MVs and HPLC. The MV samples were extracted in a solution of 9 parts 
dichloromethane: 1 part propan-2-ol with gentle mixing. Following protein precipitation (10% TCA) 
and centrifugation the supernatant was removed and 20 μ l used for multistep gradient HPLC using a C18 
column with UltiMate 3000 variable-wavelength detector. The mobile phase of 0.5% H3PO4/acetonitrile 
was pumped at 1 ml/min. The UV detector was set at 254 nm for a total run time of 23 min alternating 
flow between acetonitrile and phosphoric acid. As the system uses an automated sampler, all pre-made 
samples and MTX standards 3.06, 6.125, 12.25, 50 and 100 μ M, were run on the system in duplicate at 
a sequence time of 12 min and peaks observed at UV Vis 302 nm. With the retention time for MTX 
established at 12.5 min, the Chromeleon software of the Dionex D3 system was used to produce specific 
high resolution chromatographs of the drugs.
Docetaxel uptake in PC3 cells.  PC3 cells were attached at 1 × 105 cells per well in 6-well plates over 
24 h. Cells were then treated with CP (20 μ M) and DTX (100 nM) and after 2 h, cells were washed four 
times and lysed (0.7% NP40; Tris.Cl, pH 7.4; 70 mM EDTA; 200 nM NaCl on ice for 10 min). After pro-
tein quantitation, (BCA assay) the sample was extracted with acetonitrile and the supernatants (15,000 g; 
15 min) analysed by HPLC to determine DTX concentration, the result being normalised to nmol DTX 
per mg of cell protein.
Xenograft  model  of  human  prostate  cancer.  Male, 6–8 week old athymic nude mice (nu/nu) 
(8 mice per group) were injected i.p. in each flank with 5 × 106 PC3 cells (suspended in 100 μ l PBS). 
After about 7 days, once the tumors became palpable, usually reaching an average volume of 100 mm3, 
weekly therapy was started, tumor growth being monitored 3 times weekly using calipers to estimate 
tumor volume from the formula V = (length × width × height) × 0.52. Besides the drugs DTX and 
MTX, alone, or with calpeptin (CP) injected at 10 mg/kg, 1 h before drugs, mice were also treated weekly 
by intratumoral (i.t.) injection of 10 μ g siRNA with 7 μ l OligofectamineTM (Invitrogen). Throughout, mice 
were weighed twice weekly. Mice were sacrificed before reaching the maximum tumor size of 2000 mm3. 
At necropsy, excised tumors were weighed, fixed in 10% buffered formalin, and embedded in paraffin 
for immunohistochemical analysis. Blood samples were collected on 200 μ l of 0.13 M sodium citrate and 
MVs isolated as described before24, labeled with AnV-FITC for 15 min at RT and then diluted in 500 μ l 
binding buffer. Samples were analysed by nanosight tracking analysis as described above.
Immunohistochemical analysis of resected xenografts. Before immunohistochemical analysis, 
the 5 μ m tissue sections were deparaffinized in xylene and dehydrated as described before28. Antigen 
retrieval for anti-Ki-67 staining required boiling in 5 mM citrate buffer for 15 min. To block non-specific 
sites, samples were incubated for 1 h at RT with 5% BSA. All antibodies (rat anti-mouse CD31 (PECAM-1), 
www.nature.com/scientificreports/
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BD, Pharmingen; rabbit monoclonal anti-human Ki-67 (1:200), DAKO, Denmark) were diluted in 10 mM 
Tris-HCl buffer (pH 7.8) and 1.0% BSA (w/v). After incubation with primary antibody, tissue sections 
were given three 10 min washes in Tris buffer, and incubated with HRP-conjugated anti-rabbit or mouse 
IgG (1:100, DakoCytomation) for 2 h at RT. Peroxidase activity was developed using diaminobenzidine28. 
The tissue sections were counter-stained with haematoxylin and negative controls were stained without 
primary antibody or with pre-immune serum. For each section, eight random fields were scored inde-
pendently by two technicians in a blinded manner. Processing of resected tumors for this research was 
carried out according to the standard guidelines of the School of Human Sciences Ethics Committee.
In vivo detection of apoptosis via TUNEL assay.  To detect apoptotic cells in resected tumors, ter-
minal deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining was carried out 
using the TdT In Situ Apoptosis Detection Kit (R&D Systems) according to the manufacturer’s instruc-
tions. Light microscopy was used to calculate the percentage of apoptotic (TUNEL-positive cells).
Statistical analysis. Data are presented as the mean ± S.E.M. for each experimental group, the dif-
ferences between these groups being analyzed by one- or two-way analysis of the variance (ANOVA). 
To determine any significance in difference of the tumor volumes between control and the various treat-
ment groups, the non-parametric Mann-Whitney U test was used. One-way ANOVA followed by the 
Bonferroni multiple comparison test was also carried out using GraphPad Prism 6 to assess inter-group 
differences. P values were two-sided (unless otherwise stated) and differences were considered signifi-
cantly different at: *p < 0.05; **p < 0.01; ***p < 0.005.
Results
MVs released from MTX-treated cells carry MTX.  The concept that MVs shed cytosolic compo-
nents from cells prompted us to look for chemotherapeutic drug in MVs released from PC3 cells placed 
in growth medium with MTX AlexaFluor 488 (Lab MTX) (10 μ M; 1 h). The isolated MVs showed 99% 
relative MTX Alexafluor fluorescence, by flow cytometry, compared to ‘healthy’ (H.MVs) isolated from 
untreated cells (Fig. 1A) as well as positive fluorescence by microscopy, Fig. 1B. PC3 cells when co-cul-
tured with MTX-bearing MVs, isolated from PC3 cells treated with Lab MTX, were found to receive a 
significant transfer of fluorescence, in a dose-dependent manner (Fig. 1C).
We also showed by HPLC that PC3 cells treated with high dose MTX (100 μ M) release MTX-bearing 
MVs, and were able to establish an average concentration within these MVs of 8.4 μ M MTX (Fig.  1D 
and Supplementary Figs 2 and 3).
Downregulation of calpain expression with siRNA decreased MV release from PC3 cells and 
increases drug-induced apoptosis in PC3 cells. To further investigate the role of calpain in MV 
release, we carried out a knockdown of both μ - and m-calpain isoforms using calpain small-subunit 1 
small interfering RNA (CAPNSI siRNA). Firstly, PC3 cells were transfected with CAPNS1 siRNA. After 
fixation and permeabilisation, anti-CAPNS1 labelled cells were analysed using the Express plus assay 
by flow cytometry, Fig.  2A, and by Western blotting, Fig.  2B, which confirmed effective silencing. In 
addition to pharmacological reduction of microvesiculation, using CP, (Supplementary Fig. S4a) there-
fore, knockdown of CAPNS1 expression significantly reduced MV release from DTX-treated PC3 cells 
(Fig. 2C), resulting in a one third elevation of the intracellular concentration of DTX as determined by 
HPLC assay (Fig. 2D). Furthermore, PC3 cells silenced for CAPNS1 when treated with DTX (Fig. 3A) 
and MTX (Fig. 3B) at 100 nM for just 24 h already showed increased susceptibility to chemotherapy com-
pared to control cells, although a non-significant increase was obtained with 5 nM siRNA in conjunction 
with MTX (Fig. 3B).
Inhibition of calpain elevates drug-induced apoptosis of prostate cancer cells PC3, LnCaP 
and Du-145  cells  and  further  limits proliferation of PC3.  We postulated that MV release from 
cancer cells during chemotherapy expels drugs thereby facilitating cell survival and that if MV release 
could be inhibited (initially using CP), lower concentrations of chemotherapeutic drug could still achieve 
significant levels of apoptosis.
When MV release was inhibited in cells by pre-treatmetn with CP, thereby allowing intracellular levels 
of DTX and MTX to accumulate, significant cell death was observed, and proliferation was noticeably 
reduced, even with cells given reduced doses of drug (Fig.  4A–C, respectively). To confirm that MV 
release was occuring as a result of DTX/MTX-induced apoptosis and that this was inhibitable with 
CP, we found CP to more than halve numbers of MVs released from PC3 cells upon stimulation with 
DTX- (10 nM) (Supplementary Fig. S4A). We further identified a typical forward/side scatter tapering 
distribution dot plot by flow cytometry, with high levels of annexin V labeling (Supplementary Fig. S4B). 
NTA analysis showed a wide size distribution of MVs, peaking at 250 nm in diameter (Supplementary 
Fig. S4C) and electron microscopy revealed a characteristic morphology (Supplementary Fig. S4D). 
DTX/MTX combination therapy induced slightly more apoptosis after 48 h, compared to monotherapy 
(comparing Fig.  4E  with  A  and  D), and the addition of CP resulted in much higher apoptosis (~65% 
as opposed to ~25%) at 48 h with 10 nM DTX. These findings were repeated with one more androgen 
independent cell line, DU-145 (like PC3) and an androgen sensitive one, LnCaP (Supplementary Fig. S5).
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In a xenograft model of prostate cancer, inhibition of MV release with CP decreased tumor 
volume, intratumoral vascularization and cell proliferation whilst enhancing levels of apop-
tosis. In the xenograft PCa mouse model, 7d after intraperitoneal injection of PC3 cells, and once 
tumors had become palpable, treatment was commenced according to the schedule in Fig. 5A. Mice were 
either treated with DTX or MTX together with CP intraperitoneally (i.p.) (Fig. 5B) or with intratumoral 
(i.t.) co-injections of CAPNS1 siRNA (Fig.  5C). After three weekly treatments, immediately following 
euthanasia, resected tumors were subjected to IHC, and plasma MV levels determined.
Treatment with 10 mg/kg CP allowed a 100-fold lower dose of both DTX (Fig. 5D) and MTX (Fig. 5F) 
that could still bring about significant reductions in tumor volumes (Fig. 5D,F) as well as tumor weights 
(Fig. 5E,G), after 3 weeks. Tumor volumes (Fig. 5D) and weights on excision (Fig. 5E) were also reduced, 
when mice were injected weekly with siRNA targeting CAPNS1 in combination with 0.1 mg/kg DTX. 
Plasma MV levels of CP-treated mice showed a concomitant small decrease (Supplementary Figure S6A) 
and body weight did not fall during the 3-week course of the experiment (Supplementary Fig. 6B), 
indicating no systemic toxic side effects. To gain an insight into MV levels in the xenograft tumor, we 
had additionally made single-cell suspensions from excised xenograft tumors from two mice given CP 
versus control to measure MV release from the cells. Although the results inferred reduced MVs/g tumor 
following CP administration, i.p., the procedure was considered unreliable.
DTX, besides being a chemotherapeutic drug used in PCa is also anti-angiogenic29. As expected, DTX 
treatment (10 mg/kg) itself decreased vascularization in tumor tissues as assessed by the surface area per 
field scoring positive (Fig.  6A,D) and this reduction was enhanced in the presence of CP (10 mg/kg). 
Thus although the reduction of xenografted PC3 tumor growth could be partly due to the decreased 
vascularisation, apoptosis and proliferation levels needed to be considered in the resected tumors.
A TUNEL assay further confirmed apoptosis in PC3 tumors collected after 3 weeks of DTX treat-
ment (10 mg/kg) having induced a six-fold increase in the number of TUNEL-positive apoptotic cells 
Figure 1. Labeled MTX in MVs released from PC3 cells transfer fluorescent drug to recipient cells. 
PC3 cells (5 × 104/well) were treated with 10 μ M labeled MTX Alexafluor 488. MVs from these cells were 
shown to carry fluorescent MTX (A,B) (where Bar is 500 nm at X60 magnification using a 1 × 81 motorized, 
inverted fluorescence microscope; Olympus). Upon addition to healthy, recipient PC3 cells (5 × 105/well) in 
different ratios drug transfer was demonstrated (C). The concentration of MTX in MVs released from cells 
treated with 100 μ M MTX was shown by HPLC to be 8.4 μ M; the standard curve and chromatograph of 
MTX-bearing MVs is shown in (D) (and associated chromatographs in Figs S2 and S3).
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compared with control and which was enhanced a further 6% with CP (Fig. 6B,D). We also found a sig-
nificant inhibition of proliferation (% of Ki-67 positive cells) (Fig. 6C,D) and that CP (10 mg/kg) further 
reduced the levels of proliferating tumor cells, treated with DTX, by 15% (p < 0.05).
In summary, the in vivo model showed that the reduced PC3 tumor growth following combined 
treatment with DTX and CP which was likely to be the result of decreased intratumoral vascularisation, 
decreased proliferation and enhanced apoptosis of PC3 cells, had been potentiated by inhibiting microve-
siculation of tumor cells, using CP.
Discussion
Release of MVs carrying apoptotic enzymes, such as caspase-3, from cells undergoing intracellular stress, 
occurs as a defence against apoptosis23. As we noted recently in a review on the role of MVs in drug 
resistance30, inhibiting MV release allows caspase-3 levels to accumulate within stressed cells such that 
they succumb to apoptosis. Our review also alluded to another study which suggested that MVs laden 
with chemotherapeutic drugs may be released from cells resistant to chemotherapy31. The involvement of 
both P-gp and MRP1, as efflux transporters in MDR, as mentioned earlier first suggested a ‘non-genetic’ 
Figure 2. Silencing CAPNS1 in PC3 cells reduces DTX-stimulated MV release and pharmacological 
inhibition of calpain increases cellular concentrations of DTX. PC3 cells were transfected with CAPNS1 
siRNA#6 (5 and 50 nM) and incubated at 37 °C/5% CO2 for 48 h. Decreased CAPNS1 expression was shown 
by flow cytometry (A) and Western blotting (B) resulting in cells with a reduced capacity for MV release 
(C). Intracellular DTX in PC3 cells was assayed by HPLC following DTX treatment and showed an increase 
when microvesiculation was inhibited, by pretreatment with CP (20 μ M) (D).
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mechanism involving MVs transferring P-gp from MDR leukemic cells to drug-sensitive target cells6. 
These findings led us to explore a new hypothesis that MVs released upon treatment of cancer cells with 
chemotherapeutic agents can shed such drugs, and importantly to address whether inhibition of such 
MV release could ameliorate MDR in cancer.
The antimetabolite drugs MTX (and 5-FU) have been implicated in MDR and importantly the treat-
ment of cancer patients with MTX (or DTX) leads to significant side effects due to the higher doses 
used. Here we show that these drugs when administered with CP could be given at doses up to 100 
times lower and still induce effective killing of target PCa cells. This suggests a number of strategies 
that may be important for cancer therapeutics and indeed other diseases where cells may shed drugs 
through MVs. Specifically, we report a novel mechanism involving cancer cell expulsion of anticancer 
drugs via the release of MVs. We show for the first time that inhibition of this release through pretreat-
ment of PCa PC3 cells with the membrane-permeant calpain inhibitor, CP, or by silencing the calpain 
gene, results in elevated levels of intracellular DTX, as had been previously suggested might happen for 
cytotoxic drugs in tumor cells treated with inhibitors of MV biogenesis32 and we showed recently with a 
novel inhibitor of microvesiculation33. This achieves a sensitization of cancer cells to DTX- (and MTX-) 
mediated apoptosis (Fig. 7). The capacity to inhibit MV release and to sensitize cells to chemotherapy is 
likely to also have an opposing effect by inhibiting removal of efflux transporters on individual cells but 
even that may not be important in view of the simultaneous limitation of MV-mediated transfer of such 
transporters to other cells.
In the process of MV release, activation of calpain, a Ca2+-dependent cysteine protease, able to cleave 
cytoskeletal actin filaments, may be instrumental. As well as CP sensitising cancer cells to chemotherapy 
by inhibiting MV release, we were aware that CP is a rho kinase activator capable of inhibiting calpains 
involved in apoptosis and cell cycle progression. By inhibiting apoptosis34,35, CP might by contrast mod-
ulate the effectiveness of chemotherapy in vivo. However, as we showed in our study CP had an overall 
effect of enhancing drug-induced early apoptosis, even in vivo. Indeed, in work on cancer therapies 
against breast cancer, combination therapy of calpeptin with histone deacetylase inhibitors was found to 
be beneficial36, and paradoxically calpain is often pro-apoptotic, cleaving and activating several apoptosis 
promoting substrates such as p5337–40.
Besides its role in microvesiculation, the calpains are an important family of proteases in cancer, 
whose abnormal expression has been implicated in various cancers, and which may be a factor in deter-
mining sensitivity to cancer therapy41; indeed m-calpain (calpain II) cDNA expression was increased 
Figure 3. Apoptosis levels induced with DTX or MTX are significantly increased upon silencing 
CAPNS1 in PC3 cells. Silencing calpain in PC3 cells significantly increased apoptosis levels induced with 
DTX (A) or MTX (B) after 24 h. CAPNS1 silenced PC3 cells (transfected with siRNA#6) were washed and 
treated with DTX or MTX (100 nM) for 24 h and apoptosis levels assessed using Viacount. Control CP-
treated cells were given 20 μ M CP.
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Figure 4. DTX- and MTX-treated PCa cells undergo significant apoptosis when pretreated with 
calpeptin. Semiconfluent PC3 cells (5 × 104/well) were treated with a range of concentrations of DTX and 
MTX in the presence or absence of CP (45 min; 20 μ M) and assessed for apoptosis with ViaCount by flow 
cytometry after 48 h. CP pretreatment significantly abrogated DTX-induced apoptosis (A,C) and further 
limited DTX-mediated inhibition of proliferation (B,C) as well as MTX- and DTX + MTX- mediated 
apoptosis (D,E). Data presented are mean ± S.E.M. from three independent experiments performed in 
triplicate.
www.nature.com/scientificreports/
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Figure 5. Mouse intraperitoneal xenograft model of prostate cancer shows enhanced reduction of tumor 
volume when chemotherapy is combined with pharmacological inhibition or siRNA gene silencing of 
calpain, to reduce MV release. The flow chart schedule (A) and experimental details and analyses carried 
out (B,C) resulted in tumor volume measurements (D,F) and terminal tumor weights (E,G) showing 
enhanced reductions following chemotherapy in the presence of CP. H, images of excised PC3 xenograft 
tumors in nude mice; Bar in ‘vehicle’ image, 5 mm and 6 mm in rest.
www.nature.com/scientificreports/
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Figure 6. Pharmacological inhibition of calpain enhances DTX-mediated effects on angiogenesis, cell 
proliferation and apoptosis. Calpain inhibition with 10 mg/kg CP, i.p., enhances DTX-mediated inhibition 
of angiogenesis (10 mg.kg, i.p.) compared to DTX alone (10 mg/kg) as seen by decreases in vascular 
density (A,D) (% mouse CD31 (or PECAM-1) positive cells, blood vessels being identified as open lumens 
expressing at least one CD31+ cell), increases in apoptosis (B) (% TUNEL-positive cells) and decreases 
in numbers of proliferating cells (C) (% Ki-67 positive cells) in resected PC3 tumors, representative 
immunohistochemical staining respectively shown in (D).
www.nature.com/scientificreports/
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by 20% in localized and 40% in metastatic prostate tumors compared to benign prostate and may be 
implicated in tumorigenesis42.
In this study we have inhibited MV release to prevent cancer cells shedding chemotherapeutic drugs. 
Both in vitro and in a xenograft model of PCa, 20–100-fold lower concentrations of DTX given together 
with CP matched the reductions in tumor volume achieved with DTX alone. In this study CP barely 
induced apoptosis. That in combination with DTX, apoptosis levels were increased means that the 
enhancing effect observed is not likely to be due to synergy and that some other mechanism must explain 
the observations; further supporting this, the same effect was observed with MTX, a chemotherapeutic 
drug with a different mechanism of action. We believe, whilst noting that at other concentrations, CP 
may indeed induce apoptosis, that, the increased sensitivity to DTX must be due to the increased dose 
of DTX available to the cell.
Although this strategy to enhance the levels of delivered drugs to diseased cells is very promising and 
may have wider applications in drug delivery, it still needs to be refined. New calpain inhibitors are being 
developed with higher specific activities43 which would need to be assessed. During the course of our work 
on MVs, we and others have used a host of inhibitors, including calpeptin, and methyl-β -cyclodextrin, as 
well as glyburide (unpublished), to abrogate MV release44. We are currently determining the specificity 
of proposed microvesiculation inhibitors and testing new ones, but perhaps alongside this, and for the 
same reason, inhibition of exosome release (exocytosis), should also be considered as an approach to 
tackle chemotherapy resistance.
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